新型小鼠模型再现心梗、斑块破裂与卒中,髓过氧化物酶抑制改善生存
研究构建了SR-BI∆CT/∆CT/Ldlr-/-小鼠模型,喂食西方饮食26周后出现自发性斑块破裂、心肌梗死和卒中,死亡率高(>80%)。使用髓过氧化物酶抑制剂AZM198治疗可显著改善生存(>90%)并降低斑块破裂、心梗和卒中发生率(>60%)。该模型可模拟晚期人类动脉粥样硬化事件,用于新药筛选。
要点
- SR-BI∆CT/∆CT/Ldlr-/-小鼠喂食西方饮食26周可发生自发性斑块破裂、心梗和卒中。
- 该模型死亡率>80%,并显示高敏肌钙蛋白I升高和中性粒细胞胞外诱捕网形成增加。
- AZM198抑制髓过氧化物酶可改善生存>90%并减少斑块破裂、心梗和卒中>60%。
核心结论
- SR-BI∆CT/∆CT/Ldlr-/-小鼠喂食西方饮食26周可再现晚期人类动脉粥样硬化临床事件,并可用于测试预防主要不良心血管事件的新药。
研究设计与样本
- 研究构建了SR-BI C端突变联合Ldlr敲除的小鼠模型(SR-BI∆CT/∆CT/Ldlr-/-),喂食西方饮食26周,分析心梗、卒中及斑块稳定性,并以AZM198治疗验证模型效用。
主要发现
- SR-BI∆CT/∆CT/Ldlr-/-小鼠喂食西方饮食26周后因主要不良心血管事件(包括自发性斑块破裂伴心梗和卒中)死亡率>80%。
- 与对照小鼠相比,喂食西方饮食的SR-BI∆CT/∆CT/Ldlr-/-小鼠循环高敏肌钙蛋白I升高,病变内中性粒细胞胞外诱捕网形成增加。
- AZM198治疗使喂食西方饮食的SR-BI∆CT/∆CT/Ldlr-/-小鼠生存改善>90%,斑块破裂、心梗和卒中发生率降低>60%,并降低循环高敏肌钙蛋白I和病变内中性粒细胞胞外诱捕网形成。
临床怎么用
- 该模型可用于筛选和测试预防主要不良心血管事件的潜在新药,如髓过氧化物酶抑制剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thromboembolic events, including myocardial infarction (MI) or stroke, caused by the rupture or erosion of unstable atherosclerotic plaques are the leading cause of death worldwide. Although most mouse models of atherosclerosis develop lesions in the aorta and carotid arteries, they do not develop advanced coronary artery lesions. Moreover, they do not undergo spontaneous plaque rupture with MI and stroke or do so at such a low frequency that they are not viable experimental models to study late-stage thrombotic events or to identify novel therapeutic approaches for treating atherosclerotic disease. This has stymied the development of more effective therapeutic approaches for reducing these events beyond what has been achieved with aggressive lipid lowering. Here, we describe a diet-inducible mouse model that develops widespread advanced atherosclerosis in coronary, brachiocephalic, and carotid arteries with plaque rupture, MI, and stroke. METHODS: We characterized a novel mouse model with a C-terminal mutation in the scavenger receptor class B, type 1 (SR-BI), combined with Ldlr knockout (designated SR-BI∆CT/∆CT/Ldlr-/-). Mice were fed Western diet (WD) for 26 weeks and analyzed for MI and stroke. Coronary, brachiocephalic, and carotid arteries were analyzed for atherosclerotic lesions and indices of plaque stability. To validate the utility of this model, SR-BI∆CT/∆CT/Ldlr-/- mice were treated with the drug candidate AZM198, which inhibits myeloperoxidase, an enzyme produced by activated neutrophils that predicts rupture of human atherosclerotic lesions. RESULTS: SR-BI∆CT/∆CT/Ldlr-/- mice show high (>80%) mortality rates after 26 weeks of WD feeding because of major adverse cardiovascular events, including spontaneous plaque rupture with MI and stroke. Moreover, WD-fed SR-BI∆CT/∆CT/Ldlr-/- mice displayed elevated circulating high-sensitivity cardiac troponin I and increased neutrophil extracellular trap formation within lesions compared with control mice. Treatment of WD-fed SR-BI∆CT/∆CT/Ldlr-/- mice with AZM198 showed remarkable benefits, including >90% improvement in survival and >60% decrease in the incidence of plaque rupture, MI, and stroke, in conjunction with decreased circulating high-sensitivity cardiac troponin I and reduced neutrophil extracellular trap formation within lesions. CONCLUSIONS: WD-fed SR-BI∆CT/∆CT/Ldlr-/- mice more closely replicate late-stage clinical events of advanced human atherosclerotic disease than previous models and can be used to identify and test potential new therapeutic agents to prevent major adverse cardiac events.
引用
- Shamsuzzaman, Deaton, Salamon, et al. Novel Mouse Model of Myocardial Infarction, Plaque Rupture, and Stroke Shows Improved Survival With Myeloperoxidase Inhibition. Circulation. 2024. PMID: 38881440. doi:10.1161/CIRCULATIONAHA.123.067931
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。